Meeting
2014 Gastrointestinal Cancers Symposium
A prospective multicenter observational study for chemotherapy-induced nausea and vomiting in gastric cancer in Japan.
Authors
Shiro Iwagami
Department of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan
Shiro Iwagami , Hideo Baba , Naoki Hirabayashi , Yoichi Sugiyama , Go Nakajima , Yasushi Tsuji , Chikara Kunisaki , Akira Tsuburaya , Masahiro Goto , Yoshihiko Maehara , Koji Takeda , Kazuhiro Yoshida , Keisuke Aiba
Organizations
Department of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan, Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan, Department of Surgery Hiroshima City Asa Hospital, Hiroshima, Japan, Department of Surgery, Hiroshima City Asa Hospital, Hiroshima, Japan, Tokyo Women's Medical University, Tokyo, Japan, Department of Medical Oncology, KKR Sapporo Medical Center Tonan Hospital, Sapporo, Japan, Gastroenterological Center, Yokohama City University, Yokohama, Japan, Kanagawa Cancer Center, Yokohama, Japan, Cancer Chemotherapy Center, Osaka Medical College Hospital, Osaka, Japan, Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, Osaka City General Hospital, Osaka, Japan, Department of Surgical Oncology, Gifu University School of Medicine, Gifu, Japan, Department of Internal medicine, Division of Clinical Oncology/Hematology, Jikei University School of Medicine, Tokyo, Japan
Research Funding
Other Foundation
Background: There has been no nationwide survey on CINV or validation of the guideline in Japan. The aim of the study was to investigate the occurrence of CINV in gastric cancer patientstreated with chemotherapy for the first time. Methods: A nationwide survey on CINV was conducted by the CINV study group of Japan. 108 institutions participated in the study. A 7-day diary for CINV was provided to the patients prior to chemotherapy to record the daily occurrence and severity of CINV and the amount of food intake. Acute and delayed CINV was defined as nausea and vomiting which developed within or later than 24 hours after the start of chemotherapy, respectively. We evaluated the frequency and the risk factors of CINV. The medical staff also filled out questionnaires about their patients’ CINV. Results: A total of 154 patients were registered during the period from April 2011 to December 2012. There were 109 males and 45 females with a median age of 65 (range: 25-82). HEC was given to 152 and MEC was administered to 2 patients. CDDPwas included in all of HEC regimens. For preventing CINV, a three-drug regimen of aprepitant, 5-TH3 receptor antagonist (5- TH3 RA ), and dexamethasone was applied in 131 cases and a two-regimen of 5- TH3 RA and dexamethasone in 23. Acute nausea (AN) was ovserved in 19 patients (12.3%), while delayed nausea (DN) was experienced by 74 patients (48%). Acute vomiting (AV) occurred in 1 case (0.6%), while delayed vomiting (DV) was observed 15 cases (9.7%). The risk factors of CINV in gastric cancer were female and motion sickness. The age, pregnancy or morning sickness didn’t show any correlation with an occurrence of CINV. The staff predicted an occurrence of AN and DN in 96 patients (62.3%) and 132 (85.7%). However only experienced 19 (12.3%) and 74 (48.1%) patients showed symptoms of AN and DV, respectively. Conclusions: CINV in patients with gastric cancer seems to be under control with a management according to the guideline, however delayed CINV remains to be high and needs to be targeted by further investigation. Clinical trial information: UMIN000005971.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000005971
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 155)
DOI
10.1200/jco.2014.32.3_suppl.155
Abstract #
155
Poster Bd #
E23
Abstract Disclosures
Similar Abstracts
Abstract
2023 ASCO Annual Meeting
A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study.
First Author: Venkatraman Radhakrishnan
Abstract
2024 ASCO Gastrointestinal Cancers Symposium
Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab + chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies.
First Author: Kohei Shitara
Abstract
2022 ASCO Annual Meeting
Efficacy of olanzapine, netupitant, and palonosetron in controlling nausea and vomiting associated with highly emetogenic chemotherapy in patients with breast cancer (OLNEPA).
First Author: Camilla Vieira de Reboucas
Abstract
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
First Author: Kohei Shitara